Ronen Segal - Alpha Tau Chief Officer

DRTS Stock  USD 2.32  0.02  0.87%   

Insider

Ronen Segal is Chief Officer of Alpha Tau Medical
Age 51
Address Kiryat Hamada Street 5, Jerusalem, Israel, 9777605
Phone972 3 577 4115
Webhttps://www.alphatau.com

Alpha Tau Management Efficiency

The company has return on total asset (ROA) of (0.2192) % which means that it has lost $0.2192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3317) %, meaning that it created substantial loss on money invested by shareholders. Alpha Tau's management efficiency ratios could be used to measure how well Alpha Tau manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.37 in 2024, whereas Return On Tangible Assets are likely to drop (0.29) in 2024. At this time, Alpha Tau's Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 669.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.5 M in 2024.
Alpha Tau Medical currently holds 13.28 M in liabilities. Alpha Tau Medical has a current ratio of 41.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpha Tau's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Scott CorningOcular Therapeutix
N/A
Peter RhodeHCW Biologics
66
MBA MDEliem Therapeutics
63
Eric OlsonTenaya Therapeutics
N/A
Rabia MDOcular Therapeutix
55
Jason CPAMediciNova
46
Bruce ConklinTenaya Therapeutics
N/A
MD MPHEyenovia
48
Alexander LoboEyenovia
N/A
MS MBAInozyme Pharma
47
Seth LewisMolecular Partners AG
N/A
Alexander ZurcherMolecular Partners AG
49
Thomas BaetzGenfit
49
Pr StaelsGenfit
61
Stefanie MagnerGenfit
43
Philip StrassburgerOcular Therapeutix
64
Pascal CaiseyGenfit
55
Robert MBAEliem Therapeutics
56
Erin LavelleEliem Therapeutics
47
MA MSInozyme Pharma
N/A
Pascal PrigentGenfit
55
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of solid cancer In Israel and the United States. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. Alpha Tau is traded on NASDAQ Exchange in the United States. Alpha Tau Medical (DRTS) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hamada Street 5, Jerusalem, Israel, 9777605 and employs 121 people. Alpha Tau is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Alpha Tau Medical Leadership Team

Elected by the shareholders, the Alpha Tau's board of directors comprises two types of representatives: Alpha Tau inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpha. The board's role is to monitor Alpha Tau's management team and ensure that shareholders' interests are well served. Alpha Tau's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpha Tau's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert MD, Chief Board
Rebecca Becker, Vice legal
Pr Kelson, Chief Board
Yael Zeiger, Corporate Controller
Raphi Levy, Chief Officer
Peter Melnyk, Chief Officer
Pr Keisari, Chief board
Ronen Segal, Chief Officer
Uzi Sofer, CEO Chairman
Amnon Gat, Chief Officer

Alpha Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpha Tau a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alpha Stock Analysis

When running Alpha Tau's price analysis, check to measure Alpha Tau's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpha Tau is operating at the current time. Most of Alpha Tau's value examination focuses on studying past and present price action to predict the probability of Alpha Tau's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpha Tau's price. Additionally, you may evaluate how the addition of Alpha Tau to your portfolios can decrease your overall portfolio volatility.